Company Overview Sample Clauses
The Company Overview clause provides a summary of the business entity that is party to the agreement, outlining its legal identity, structure, and core activities. Typically, this section includes the company's registered name, jurisdiction of incorporation, principal place of business, and a brief description of its operations or industry focus. By clearly establishing the company's background and legal standing, this clause ensures all parties have a shared understanding of who is entering into the contract, reducing ambiguity and supporting the enforceability of the agreement.
Company Overview. The business profile must include an overview of the business structure and operation of the Proposer’s firm. The company overview should include, at a minimum, all the following items:
1) The Proposer’s business name, physical location, mission statement, legal business status, annual sales, and current staffing levels.
2) A detailed description of the Proposer’s current and previous business activities, including, without limitation:
a. The history of the Proposer’s business, including, without limitation, the date when the business was founded and how innovation and high-quality performance is fostered to comply with the requirements of this RFP.
b. The number of years the Proposer has been operating under the present business name, and any prior business names under which the Proposer has provided services equivalent to those set forth in this RFP.
c. The number of years the Proposer has been providing services at airports equivalent to those set forth in this RFP.
d. The total number of airports or similar commercial operations for which the Proposer has provided services equivalent to those set forth in this RFP, specifically utilizing the technology and equipment that is being proposed.
3) A detailed description of any litigation regarding the provision of services equivalent to those set forth in this RFP that has been brought by or against the Proposer, including, without limitation, the nature and result of such litigation, if applicable.
4) A detailed description of any fraud convictions related to the performance of public contracts, if applicable.
5) A detailed description of any current or prior debarments, suspensions or other ineligibility to participate in public contracts, if applicable.
6) A detailed description of any violations of local, state and/or federal industry or regulatory requirements, if applicable.
7) A detailed description of any controlling or financial interest the Proposer has in any other firms or organizations, or whether Proposer’s business is owned or controlled by any other firm or organization. If the Proposer does not hold a controlling or financial interest in any other firms or organizations, that must be stated.
Company Overview. Founded in 1983 and incorporated in 1988. • The firm has grown from two employees to a staff of over 40 full time associates in multiple states. Average tenure with the company is 7 years and employee turnover is less than 10%. • HydroCorp Conducts over 25,000 on site, Cross-Connection Control Inspections annually. • HydroCorp provided Cross-Connection Control Program Management Services to over 240 communities in several states including: Michigan, Wisconsin, Delaware, Maryland, Virginia, Florida and Minnesota. We still have our first customer! • Our highly trained staff works in an efficient manner in order to achieve maximum productivity and keep program costs affordable. We have a detailed system and process that each of our field inspectors follow in order to meet productivity and quality assurance goals. • Our municipal inspection team is committed to providing outstanding customer service to the water users in each of the communities we serve. We teach and train customer service skills in addition to the technical skills since our team members act as representatives of the community that we service. • Our municipal inspection team has attended training classes and received certification from the following recognized Cross Connection Control Programs: UF TREEO, UW-Madison, USC – Foundation for Cross Connection Control and Hydraulic Research, American Backflow Prevention Association (ABPA), and American Society for Sanitary Engineering (ASSE). We invest heavily in internal and external training with our team members to ensure that each Field Service and Administrative team member has the skills and abilities to meet the needs of our clients. • Our administrative staff can answer most technical calls related to the cross-connection control program and have attended basic cross-connection control training classes. • HydroCorp staff and company are active members in many water industry associations including: o American Water Works Association (AWWA) | AWWA – Wisconsin Chapter o National Rural Water Association (NRWA) | Wisconsin Rural Water Association o American Public Works Association (APWA) • HydroCorp is not a Plumbing Company and does not utilize existing staff to perform backflow prevention assembly testing, repair or plumbing related services.
Company Overview. Backpack Exchange operates entities around the world to provide its Services to customers. You acknowledge and agree that the Specified Services shall be provided to Users in the Applicable Jurisdictions by the applicable Service Provider, in each case as set forth in Schedule A. In such case, the Specified Services shall be provided to you by the applicable Service Provider on and subject to this Agreement, with references in these general terms to Backpack Exchange being read as references to the Service Provider specified in Schedule A, unless the context provides otherwise, and under no circumstances shall any other person, including any affiliate of the Service Provider, be liable to you for the performance of any of the Service Provider’s obligations under this Agreement. All of the Service Providers are affiliates of Trek Labs Ltd, a company registered in the British Virgin Islands under the registration number 2120162 with its registered office at ▇▇▇▇▇▇ House, Wickhams Cay II, PO Box ▇▇▇▇, ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ Islands.
Company Overview i. State the Firm’s legal entity name and headquarters address.
ii. Firms must provide the name, title, address, telephone number, and email of the individual responsible for acting as the Firm’s designated representative for these services.
iii. Identify key personnel on behalf of the Firm who may be involved with providing the Scope of Services detailed within the RFP. Provide a resume, or summary of work history, for each of these individuals.
Company Overview. TerreStar Networks Inc. is a Reston, Virginia-based provider of advanced mobile communications services for the North American market. TerreStar plans to launch an innovative communications system to provide mobile coverage throughout the US and Canada using several classes of devices from a typical handset to vehicle mounted terminals. This seamless, ubiquitous network, based on integrated satellite/ground-based technology, will allow service in even the most hard-to-reach areas, and will finally allow for the interoperable, survivable and critical communications infrastructure that our nation’s first responders need. The TerreStar hybrid network will provide advanced IMS based 3.5/4G communication services for government, enterprise and personal customers. More information is available at htt▇://▇▇▇.▇▇▇▇▇▇▇▇▇.▇▇▇/
Company Overview. We endeavor to become the leader in discovery, development, and commercialization of therapeutic agents capable of addressing significant unmet medical need via the application of the silence and replace approach to the treatment of genetic disorders. Benitec Biopharma Inc. (“Benitec” or the “Company” or in the first person, “we” or “our”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease- causing genes following a single administration. The unique therapeutic constructs also enable the simultaneous delivery of wildtype replacement genes, facilitating the proprietary “silence and replace” approach to the treatment of genetically defined diseases. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. BB-301 is a silence and replace-based genetic medicine currently under development by Benitec. BB-301 is an AAV-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells). This fundamental therapeutic approach to disease management is called “silence and replace.” The silence and replace mechanism offers the potential to restore the normative physiology of diseased cells and tissues and to improve treatment outcomes for patients suffering from the chronic, and potentially fatal, effects of OPMD. BB-301 has been granted Orphan Drug Designation in the United States and the European Union. The targeted gene silencing effects of RNAi, in conjunction with the durable transgene expression achievable via the use of modified viral vectors, imbues the silence and replace approach with the potential to produce permanent silencing of disease-causing genes along with simultaneous replacement of the wild type gene function following a single administration of the proprietary genetic medicine. We believe that this novel mechanistic profile of the current and future investigational agents developed by Benitec could facilitate the ach...
Company Overview. Backpack Exchange operates entities around the world to provide its Services to customers. You acknowledge and agree that the “Specified Services” shall be provided to Users in the “Applicable Jurisdictions” by the applicable “Service Provider” (in each case as defined and set forth in Schedule A). In such case, the Specified Services shall be provided to you by the applicable Service Provider on and subject to this Agreement, with references in these general terms to Backpack Exchange being read as references to the Service Provider specified in Schedule A, unless the context provides otherwise, and under no circumstances shall any other person, including any Affiliate of the Service Provider, be liable to you for the performance of any of the Service Provider’s obligations under this Agreement. All of the Service Providers are affiliates of Trek Labs Ltd, a company registered in the British Virgin Islands under the registration number 2120162 with its registered office at ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇, ▇▇ ▇▇▇ ▇▇▇▇, ▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇ (“Trek Labs”).
Company Overview. My Surgery Website was founded in 2006 with the aim of providing first class, secure website systems; in 2013 My Surgery Website was acquired by Stericycle and currently forms part of the Stericycle Group.
Company Overview. MAP Retirement is a third-party administrator of retirement plans. Serving small and mid-sized businesses across all 50 states, MAP provides customers with plan design and implementation, plan administration, compliance, fiduciary services and customized support to approximately 3,700 plans and 200,000 participants. Established in 1993, MAP has over 100 employees and is headquartered in Appleton, Wisconsin.
Company Overview. We are a clinical-stage biopharmaceutical company focused on leveraging our extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Our current pipeline is entirely derived from the Bayer License Agreement, pursuant to which we have been granted an exclusive, royalty-bearing, worldwide license under certain Bayer patents and know-how to develop, use, manufacture, commercialize, sublicense, and distribute (i) a bioconjugation platform, which includes next-generation antibody- drug conjugates and small molecule-drug conjugates, and (ii) a small molecule drug program, including a P-TEFb inhibitor compound. We intend to use these product candidates to treat various cancers in a patient-specific, targeted approach. We believe that these product candidates are differentiated from current programs targeting similar cancer biology and, if approved, may improve clinical outcomes of patients with cancer. We had cash on hand of approximately $2.4 million as of January 9, 2025. We have entered into a binding term sheet (the “Term Sheet”) with Oqory, Inc., a Delaware corporation (“Oqory”), and Vivasor, Inc., Oqory’s parent corporation, relating to a proposed business combination between Vincerx and Oqory. Oqory is a private biopharmaceutical company dedicated to developing next-generation antibody-drug conjugates for the treatment of cancer, focused on the development of Oqory’s lead clinical asset, OQY-3258. OQY-3258 is an anti-TROP2 ADC with an optimized enzyme-dependent linker technology and an SN-38 payload with established efficacy and manageable side effect profile. OQY-3258 has completed Phase 1/2 development in China, treating over 150 patients with solid tumors, including metastatic HR+/HER2- and triple-negative breast cancer. Currently, OQY-3258 is being evaluated in China in a Phase 3 study as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer and in a Phase 3 study in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer. The parties currently contemplate a reverse triangular merger structure, pursuant to which (i) a subsidiary of Vincerx would merge into Oqory, (ii) Oqory stockholders would receive shares of Common Stock in exchange for their shares of Oqory common stock (“Oqory Common Stock”) based on the Exchange Ratio (as defined below), and (iii) outstanding options, warrants, and other rig...